Edition:
India

Rigel Pharmaceuticals Inc (RIGL.OQ)

RIGL.OQ on NASDAQ Stock Exchange Global Select Market

3.99USD
16 Jan 2018
Change (% chg)

-- (--)
Prev Close
$3.99
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
497,281
52-wk High
$4.47
52-wk Low
$1.94

Select another date:

Thu, Jan 4 2018

BRIEF-Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib

* RIGEL PHARMACEUTICALS - ‍FDA HAS CONFIRMED IT DOES NOT PLAN TO CONVENE ONCOLOGY DRUGS ADVISORY COMMITTEE MEETING TO DISCUSS NDA FOR FOSTAMATINIB​

BRIEF-Rigel Announces Resignation Of Ryan Maynard, Executive Vice President And CFO Effective December 31, 2017

* RESIGNATION OF RYAN MAYNARD, EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, EFFECTIVE DECEMBER 31, 2017

BRIEF-Rigel announces Q3 loss of $0.14 per share

* Rigel announces third quarter 2017 financial results and provides company update

BRIEF-Rigel announces pricing of public offering of common stock

* Says public offering of 18.1 million common shares priced at $3.35 per share Source text for Eikon: Further company coverage:

BRIEF-Rigel announces proposed public offering of common stock

* Rigel Pharmaceuticals Inc - intends to offer and sell up to $40 million of shares of its common stock in an underwritten public offering

BRIEF-RIGEL PHARMACEUTICALS SAYS FOSTAMATINIB MEETS PRE-SPECIFIED GOAL IN STAGE 1 OF AIHA PHASE 2 STUDY

* FOSTAMATINIB MEETS PRE-SPECIFIED PRIMARY ENDPOINT IN STAGE 1 OF AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA) PHASE 2 STUDY

BRIEF-Rigel provides update on FDA review of fostamatinib for ITP

* Rigel provides update on FDA review of fostamatinib for ITP

BRIEF-Rigel Q2 loss per share $0.16

* Rigel announces second quarter 2017 financial results and provides company update

Select another date: